Beard Nicole A, Sakowska Magdalena M, Dulhunty Angela F, Laver Derek R
Division of Biochemistry and Molecular Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT 0200, Australia.
Biophys J. 2002 Jan;82(1 Pt 1):310-20. doi: 10.1016/S0006-3495(02)75396-4.
We provide novel evidence that the sarcoplasmic reticulum calcium binding protein, calsequestrin, inhibits native ryanodine receptor calcium release channel activity. Calsequestrin dissociation from junctional face membrane was achieved by increasing luminal (trans) ionic strength from 250 to 500 mM with CsCl or by exposing the luminal side of ryanodine receptors to high [Ca(2+)] (13 mM) and dissociation was confirmed with sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting. Calsequestrin dissociation caused a 10-fold increase in the duration of ryanodine receptor channel opening in lipid bilayers. Adding calsequestrin back to the luminal side of the channel after dissociation reversed this increased activity. In addition, an anticalsequestrin antibody added to the luminal solution reduced ryanodine receptor activity before, but not after, calsequestrin dissociation. A population of ryanodine receptors (approximately 35%) may have initially lacked calsequestrin, because their activity was high and was unaffected by increasing ionic strength or by anticalsequestrin antibody: their activity fell when purified calsequestrin was added and they then responded to antibody. In contrast to native ryanodine receptors, purified channels, depleted of triadin and calsequestrin, were not inhibited by calsequestrin. We suggest that calsequestrin reduces ryanodine receptor activity by binding to a coprotein, possibly to the luminal domain of triadin.
我们提供了新的证据,表明肌浆网钙结合蛋白——肌集钙蛋白,可抑制天然雷诺丁受体钙释放通道的活性。通过用氯化铯将管腔(反式)离子强度从250 mM增加到500 mM,或使雷诺丁受体的管腔侧暴露于高[Ca(2+)](13 mM)来实现肌集钙蛋白从连接面膜的解离,并用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳和蛋白质免疫印迹法确认了解离。肌集钙蛋白的解离使脂质双层中雷诺丁受体通道开放的持续时间增加了10倍。解离后将肌集钙蛋白添加回通道的管腔侧可逆转这种增加的活性。此外,添加到管腔溶液中的抗肌集钙蛋白抗体在肌集钙蛋白解离之前降低了雷诺丁受体的活性,但在解离之后则没有作用。一部分雷诺丁受体(约35%)最初可能缺乏肌集钙蛋白,因为它们的活性很高,不受离子强度增加或抗肌集钙蛋白抗体的影响:当添加纯化的肌集钙蛋白时它们的活性下降,然后它们对抗体产生反应。与天然雷诺丁受体相反,去除了三联蛋白和肌集钙蛋白的纯化通道不受肌集钙蛋白的抑制。我们认为肌集钙蛋白通过与一种辅助蛋白结合,可能是与三联蛋白的管腔结构域结合,来降低雷诺丁受体的活性。